骨髓增生异常综合征骨髓微环境的改变

doi:10.3760/cma.j.issn.1673422X.2016.09.019

摘要/Abstract

摘要： 骨髓微环境是一个由造血干/祖细胞（HSPC）、非造血细胞以及细胞外基质和多种细胞因子等组成的复杂网状结构，其各成分相互作用以支持正常的造血。近来研究发现，骨髓微环境中的间充质干细胞（MSC）、髓源抑制性细胞、细胞因子功能紊乱以及造血干细胞的表观遗传学改变都可以影响正常造血，导致血液系统恶性疾病如骨髓增生异常综合征(MDS)的发生。已有动物模型证实了骨髓微环境在造血系统恶性疾病的发生和维持中起着重要作用。

关键词: 骨髓增生异常综合征, 细胞因子类, 间充质干细胞

Abstract: Bone marrow microenvironment is a complex network consisting of hematopoietic stem/progenitor cells (HSPCs), nonhematopoietic cells, extracellular matrix and various cytokines. Its components interact to support normal hematopoiesis. Emerging evidence indicates that the dysfunction of mesenchymal stem cells, myeloidderived suppressor cells, cytokines and the epigenetic alterations of HSPCs in the bone marrow microenvironment could influence normal hematopoiesis. Abnormal hematopoiesis contributes to the occurrence of hematological malignancies, such as myelodysplastic syndromes (MDS). Animal models have confirmed that bone marrow microenvironment plays an important role in the original generation and maintenance of malignant diseases of hematopoietic system.

Key words: Myelodysplastic syndromes, Cytokines, Mesenchymal stem cells

沈娜, 李青, 程范军. 骨髓增生异常综合征骨髓微环境的改变[J]. 国际肿瘤学杂志, 2016, 43(8): 715-717.

SHEN Na, LI Qing, CHENG Fan-Jun. Changes of bone marrow microenvironment of myelodysplastic syndromes[J]. Journal of International Oncology, 2016, 43(8): 715-717.

参考文献

［1］ Xiong H, Yang XY, Han J, et al. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes［J］. Braz J Med Biol Res, 2015, 48(3)： 207213. DOI: 10.1590/1414431X20144051. ［2］ Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies［J］. Leukemia, 2015, 29(2)： 259268. DOI: 10.1038/leu.2014.325. ［3］ Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia［J］. Nature, 2010, 464(7290)： 852857. DOI: 10.1038/nature08851. ［4］ Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cellscurrent trends and future prospective［J］. Biosci Rep, 2015, 35(2)： e00191. DOI: 10.1042/BSR20150025. ［5］ Falconi G, Fabiani E, Fianchi L, et al. Impairment of PI3K/AKT and WNT/betacatenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes［J］. Exp Hematol, 2016, 44(1)： 7583. DOI: 10.1016/j.exphem.2015.10.005. ［6］ Blau O, Baldus CD, Hofmann WK, et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts［J］. Blood, 2011, 118(20)： 55835592. DOI: 10.1182/blood201103343467. ［7］ Geyh S, Oz S, Cadeddu RP, et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells［J］. Leukemia, 2013, 27(9)： 18411851. DOI: 10.1038/leu.2013.193. ［8］ Johnson RC, Kurzer JH, Greenberg PL, et al. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival［J］. Am J Clin Pathol, 2014, 142(6)： 795802. DOI: 10.1309/AJCP71OPHKOTLSUG. ［9］ Cogle CR, Saki N, Khodadi E, et al. Bone marrow niche in the myelodysplastic syndromes［J］. Leuk Res, 2015, 39(10)： 10201027. DOI: 10.1016/j.leukres.2015.06.017. ［10］Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloidderived suppressor cells［J］. J Clin Invest, 2013, 123(11)： 45954611. DOI: 10.1172/JCI67580. ［11］Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets［J］. Blood, 2014, 123(19)： 30163026. DOI: 10.1182/blood201310533398. ［12］Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis［J］. Leuk Lymphoma, 2011, 52(11)： 20452049. DOI: 10.3109/10428194.2011.584002. ［13］Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS［J］. Cell Mol Life Sci, 2015, 72(10)： 19591966. DOI: 10.1007/s000180151846x. ［14］Kondo A, Yamashita T, Tamura H, et al. Interferongamma and tumor necrosis factoralpha induce an immunoinhibitory molecule, B7H1, via nuclear factorkappaB activation in blasts in myelodysplastic syndromes［J］. Blood, 2010, 116(7)： 11241131. DOI: 10.1182/blood200912255125. ［15］Kastrinaki MC, Pavlaki K, Batsali AK, et al. Mesenchymal stem cells in immunemediated bone marrow failure syndromes［J］. Clin Dev Immunol, 2013, 2013： 265608. DOI: 10.1155/2013/265608. ［16］Azizidoost S, Babashah S, Rahim F, et al. Bone marrow neoplastic niche in leukemia［J］. Hematology, 2014, 19(4)： 232238. DOI: 10.1179/1607845413Y.0000000111. ［17］Kim M, Hwang S, Park K, et al. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes［J］. PLoS One, 2015, 10(3)： e120602. DOI: 10.1371/journal.pone.0120602. ［18］Harada H, Harada Y. Recent advances in myelodysplastic syndromes: molecular pathogenesis and its implications for targeted therapies［J］. Cancer Sci, 2015, 106(4)： 329336. DOI: 10.1111/cas.12614. ［19］Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and bloodcancer risk inferred from blood DNA sequence［J］. N Engl J Med, 2014, 371(26)： 24772487. DOI: 10.1056/NEJMoa1409405. ［20］Prebet T, Gore SD, Esterni B, et al. Outcome of highrisk myelodysplastic syndrome after azacitidine treatment failure［J］. J Clin Oncol, 2011, 29(24)： 33223327. DOI: 10.1200/JCO

[1]	赵建昊, 段衍超. 多发性骨髓瘤髓外病变发病机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 55-59.
[2]	杨爱武，林志敏，张江灵，梁仁佩，郑维斌. 丁蔻理中汤对中晚期胃癌化疗患者细胞免疫因子及不良反应的影响 [J]. 国际肿瘤学杂志, 2018, 45(3): 161-165.
[3]	张洁, 方琳, 郑骏年 . 间充质干细胞介导的肿瘤治疗[J]. 国际肿瘤学杂志, 2015, 42(8): 612-615.
[4]	李蓉, 杨小芸, 沈丽达. 胃癌患者营养不良相关因子研究进展[J]. 国际肿瘤学杂志, 2015, 42(3): 221-223.
[5]	陈红姗, 王玉栋, 刘巍. 癌症相关性疲劳流行病学及发病机制研究进展[J]. 国际肿瘤学杂志, 2014, 41(3): 187-190.
[6]	蔡凯, 张闯, 江涛. 肿瘤射频消融治疗后的免疫反应及抗肿瘤效应[J]. 国际肿瘤学杂志, 2013, 40(11): 826-829.
[7]	周君君, 卢兆桐. 间充质干细胞在放射性肺损伤治疗中的展望[J]. 国际肿瘤学杂志, 2012, 39(8): 706-708.
[8]	赵大航. 生长抑制因子-4抗肿瘤作用[J]. 国际肿瘤学杂志, 2012, 39(6): 422-424.
[9]	李思雨, 赵庆华. 间充质干细胞作为载体在肿瘤治疗中的应用[J]. 国际肿瘤学杂志, 2012, 39(10): 748-751.
[10]	李彩荣, 凌斌. 间充质干细胞与肿瘤生物治疗[J]. 国际肿瘤学杂志, 2011, 38(4): 254-256.
[11]	仇有成, 徐建勇, 王存祖. 骨髓间充质干细胞在胶质瘤研究中的应用[J]. 国际肿瘤学杂志, 2011, 38(1): 24-26.